Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.55 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15848786 | 0.94 | CD69 (0.60) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL4266219 | 0.91 | CD69 (0.57) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL4266215 | 0.91 | CD69 (0.57) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL4279261 | 0.89 | CD69 (0.55) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL4279267 | 0.89 | CD69 (0.55) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL13541613 | 0.88 | CD69 (0.61) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL21211570 | 0.88 | CD69 (0.61) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL13541638 | 0.88 | CD69 (0.61) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL13663174 | 0.88 | CD69 (0.61) | CD69LGALS8LGALS3LGALS4ALDH1A1 | |
| SCHEMBL16187917 | 0.86 | CD69 (0.61) | CD69LGALS8LGALS3LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | UGCG, SMPD1, SMPD4 | CD69 1955/4885LGALS8 1702/4885LGALS3 1250/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | CD69 3355/4885LGALS8 3800/4885LGALS3 3088/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | CD69 19/4885LGALS8 407/4885LGALS3 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.